恶性肿瘤相关血栓形成的研究进展  

Progress of cancer-associated thrombosis

作　　者：龚帅[1] 豆金平[1] 樊青霞[1] 刘峰辉[1] 

机构地区：[1]郑州大学第一附属医院肿瘤科,郑州450052

出　　处：《世界临床药物》2011年第10期624-627,共4页World Clinical Drug

摘　　要：血栓性疾病是恶性肿瘤患者常见的并发症之一。恶性肿瘤相关血栓栓塞与癌基因的激活及组织因子的表达相关,与多种危险因素如肿瘤种类及分期、并发症和一些治疗药物等相关。长期应用低分子肝素抗凝治疗可降低恶性肿瘤患者静脉血栓栓塞的复发率,安全有效。本文综述恶性肿瘤相关血栓形成的机制、高危因素及其防治。Thrombosis is one of the common complications in cancer patients. The general mechanisms of cancer- associated thrombosis are related in part to oncogene activation and tissue factor expression indicated by many evidences. Several risk factors have been identified including site and stage of cancer, patient comorbidities and specific therapeutic agents. Long-term anticoagulation with low molecular weight heparin is safe and effective in reducing recurrent venous thromboembolism for those patients. This review describes the mechanisms, risk factors, prevention and treatment of cancer-associated thrombosis.

关 键 词：恶性肿瘤 血栓栓塞 发病机制 危险因素 药物评价 

分 类 号：R730.53[医药卫生—肿瘤] R543.3[医药卫生—临床医学]